Literature DB >> 3019235

Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon.

K L Hartshorn, E G Sandstrom, D Neumeyer, T J Paradis, T C Chou, R T Schooley, M S Hirsch.   

Abstract

Phosphonoformate and recombinant alpha-A interferon synergistically inhibited the replication of human T-cell lymphotropic virus type III in cultured peripheral blood lymphocytes. T-cell proliferative capability was maintained by this combination, and toxicity was minimal.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3019235      PMCID： PMC176465          DOI： 10.1128/AAC.30.1.189

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

Authors:  D D Ho; K L Hartshorn; T R Rota; C A Andrews; J C Kaplan; R T Schooley; M S Hirsch
Journal:  Lancet       Date:  1985-03-16       Impact factor: 79.321

2.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

3.  Interferon inhibits C-type virus at a posttranscriptional, prerelease step.

Authors:  A Billiau; H Heremans; P T Allens; S Baron; P de Somer
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

4.  An effect of interferon on the uncoating of murine leukaemia virus not related to the antiviral state.

Authors:  M Aboud; R Shoor; S Salzberg
Journal:  J Gen Virol       Date:  1980-12       Impact factor: 3.891

5.  Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.

Authors:  J U Gutterman; S Fine; J Quesada; S J Horning; J F Levine; R Alexanian; L Bernhardt; M Kramer; H Spiegel; W Colburn; P Trown; T Merigan; Z Dziewanowski
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

6.  Effect of interferon on murine leukaemia virus infection. IV. Formation of non-infectious virus in chronically infected cells.

Authors:  P M Pitha; N A Wivel; B F Fernie; H P Harper
Journal:  J Gen Virol       Date:  1979-03       Impact factor: 3.891

7.  Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.

Authors:  G Klintmalm; B Lönnqvist; B Oberg; G Gahrton; J O Lernestedt; G Lundgren; O Ringdén; K H Robert; B Wahren; C G Groth
Journal:  Scand J Infect Dis       Date:  1985

8.  Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells.

Authors:  E G Sandstrom; R T Schooley; D D Ho; R Byington; M G Sarngadharan; M E MacLane; M Essex; R C Gallo; M S Hirsch
Journal:  Transfusion       Date:  1985 Jul-Aug       Impact factor: 3.157

9.  Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes.

Authors:  M S Reitz; B J Poiesz; F W Ruscetti; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205
View more
  18 in total

1.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

2.  Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.

Authors:  B D Walker; M Kowalski; W C Goh; K Kozarsky; M Krieger; C Rosen; L Rohrschneider; W A Haseltine; J Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 3.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 4.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

5.  Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.

Authors:  X B Kong; Q Y Zhu; R M Ruprecht; K A Watanabe; J M Zeidler; J W Gold; B Polsky; D Armstrong; T C Chou
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro.

Authors:  S M Hammer; J M Gillis
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

7.  Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

Authors:  K L Hartshorn; M W Vogt; T C Chou; R S Blumberg; R Byington; R T Schooley; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 8.  Treatment of human immunodeficiency virus infections.

Authors:  M S Hirsch; J C Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 9.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

10.  Activation of interferon-regulated, dsRNA-dependent enzymes by human immunodeficiency virus-1 leader RNA.

Authors:  D N SenGupta; R H Silverman
Journal:  Nucleic Acids Res       Date:  1989-02-11       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.